Patents by Inventor Timur Gungor

Timur Gungor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
    Patent number: 8329718
    Abstract: The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, D and W are as defined herein. These compounds are selective inhibitors of the human P2Y1 receptor which can be used as medicaments.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: December 11, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jennifer X. Qiao, Tammy C. Wang, James C. Sutton, Timur Gungor
  • Amino-benzazoles as P2Yreceptor inhibitors with pyridine ring and heterocyclic components
    Patent number: 8053450
    Abstract: The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
    Type: Grant
    Filed: April 17, 2008
    Date of Patent: November 8, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Timothy F. Herpin, George C. Morton, Robert P. Rehfuss, R. Michael Lawrence, Michael A. Poss, Jacques Y. Roberge, Timur Gungor
  • N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS
    Publication number: 20100197716
    Abstract: The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, D and W are as defined herein. These compounds are selective inhibitors of the human P2Y1 receptor which can be used as medicaments.
    Type: Application
    Filed: April 16, 2010
    Publication date: August 5, 2010
    Inventors: Jennifer Qiao, Tammy C. Wang, James C. Sutton, Timur Gungor
  • N-linked heterocyclic antagonists of P2Yreceptor useful in the treatment of thrombotic conditions
    Patent number: 7728008
    Abstract: The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, D and W are as defined herein. These compounds are selective inhibitors of the human P2Y1 receptor which can be used as medicaments.
    Type: Grant
    Filed: June 26, 2006
    Date of Patent: June 1, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jennifer Qiao, Tammy C. Wang, James C. Sutton, Timur Gungor
  • Urea antagonists of P2Yreceptor useful in the treatment of thrombotic conditions
    Patent number: 7674828
    Abstract: The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
    Type: Grant
    Filed: May 8, 2008
    Date of Patent: March 9, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Hannguang J. Chao, Huji Tuerdi, Timothy F. Herpin, Jacques Y. Roberge, Yalei Liu, Michael R. Lawrence, Robert P. Rehfuss, Charles G. Clark, Jennifer X. Qiao, Timur Gungor, Patrick Y. S. Lam, Tammy C. Wang, Rejean Ruel, Alexandre L'Heureux, Carl Thibeault, Gilles Bouthillier, Dora M. Schnur
  • Urea antagonists of P2Yreceptor useful in the treatment of thrombotic conditions
    Patent number: 7550499
    Abstract: The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
    Type: Grant
    Filed: May 10, 2005
    Date of Patent: June 23, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Huji Tuerdi, Hannguang J. Chao, Jennifer X. Qiao, Tammy C. Wang, Timur Gungor
  • Amino-benzazoles as P2Yreceptor inhibitors
    Patent number: 7470712
    Abstract: The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
    Type: Grant
    Filed: January 19, 2005
    Date of Patent: December 30, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Timothy F. Herpin, George C. Morton, Robert P. Rehfuss, R. Michael Lawrence, Michael A. Poss, Jacques Y. Roberge, Timur Gungor
  • C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators
    Patent number: 7456188
    Abstract: The present application describes compounds according to Formula I, wherein Q, R1, R2 and X are described herein, that are useful as Estrogen Receptor Beta (ER?) modulators. Additionally, the present application describes pharmaceutical compositions containing the compounds according to Formula I and optionally additional therapeutic agents. Finally, the present application describes methods utilizing the compounds according to Formula I for modulating the function of ER? in the treatment of diseases and disorders associated with ER? such as, for example, bone disorders; cardiovascular diseases; hypercholesterolemia; hypertriglyceridemia; vasomotor disorders; urogenital disorders; prostatic hypertrophy; endometrial hyperplasia; cancer and central nervous system disorders, such as, neurodegenerative disorders.
    Type: Grant
    Filed: April 26, 2006
    Date of Patent: November 25, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: James R. Corte, John K. Dickson, Timur Gungor
  • UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS
    Publication number: 20080280905
    Abstract: The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
    Type: Application
    Filed: May 8, 2008
    Publication date: November 13, 2008
    Applicant: Bristol Myers Squibb Company
    Inventors: Hannguang J. Chao, Huji Tuerdi, Timothy F. Herpin, Jaques Yves Roberge, Yalei Liu, R. Michael Lawrence, Robert P. Rehfuss, Charles G. Clark, Jennifer X. Qiao, Timur Gungor, Patrick Y. S. Lam, Tammy Wang, Rejean Ruel, Alexandre L'Heureux, Carl Thibeault, Gilles Bouthillier, Dora M. Schnur
  • AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS
    Publication number: 20080275090
    Abstract: The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
    Type: Application
    Filed: April 17, 2008
    Publication date: November 6, 2008
    Inventors: Timothy F. Herpin, George C. Morton, Robert P. Rehfuss, R. Michael Lawrence, Michael A. Poss, Jacques Y. Roberge, Timur Gungor
  • Urea antagonists of P2Yreceptor useful in the treatment of thrombotic conditions
    Patent number: 7388021
    Abstract: The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
    Type: Grant
    Filed: May 10, 2005
    Date of Patent: June 17, 2008
    Assignee: Bristol Myers Squibb Company
    Inventors: Hannguang J. Chao, Huji Tuerdi, Timothy F. Herpin, Jacques Yves Roberge, Yalei Liu, R. Michael Lawrence, Robert P. Rehfuss, Charles G. Clark, Jennifer X. Qiao, Timur Gungor, Patrick Y. S. Lam, Tammy Wang, Rejean Ruel, Alexandre L'Heureux, Carl Thibeault, Gilles Bouthillier, Dora M. Schnur
  • 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
    Patent number: 7381730
    Abstract: Novel quinazoline derivatives possessing activity as estrogen receptor beta (ER?) modulators are provided which have the general formula I wherein X is O or S; A and B are each independently CR?? or N; R, R? and R? are each independently hydrogen, alkyl, benzyl, p-methoxybenzyl, allyl, or Si(R4)3, wherein at least one of R, R? and R? is hydrogen; R?? is hydrogen, halogen, CF3, OR5, S(O)nR6, NR7R8, cycloalkyl or alkyl; R1, R2 and R3 are each independently hydrogen, halogen, CF3, OR5, S(O)nR6, NR7R8, cycloalkyl or alkyl; R4 is a alkyl; R5, R6, R7 and R8 in each functional group are each independently hydrogen, cycloalkyl or alkyl; and n is an integer from 0 to 2. In addition, a method is provided for preventing, inhibiting or treating the progression or onset of pathological conditions associated with the estrogen receptor and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: June 3, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Timur Gungor, James R. Corte
  • Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
    Patent number: 7312218
    Abstract: The present application describes sulfonylaminovalerolactams and derivatives thereof of Formula Ia-If: or pharmaceutically acceptable salt forms thereof, wherein ring G is a mono- or bicyclic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: December 25, 2007
    Assignee: Bristol Myers Squibb Co.
    Inventors: Wei Han, Zilun Hu, Timur Gungor
  • LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS
    Publication number: 20070135428
    Abstract: The present application describes lactam-containing cyclic diamines and derivatives thereof of Formula I: P4-M-M4??I or pharmaceutically acceptable salt forms thereof, wherein M is a non-aromatic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Application
    Filed: February 16, 2007
    Publication date: June 14, 2007
    Inventors: Jennifer Qiao, Tammy Wang, Gren Wang, Timur Gungor
  • SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
    Publication number: 20070099922
    Abstract: The present application describes sulfonylaminovalerolactams and derivatives thereof of Formula Ia-If: or pharmaceutically acceptable salt forms thereof, wherein ring G is a mono- or bicyclic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Application
    Filed: December 15, 2006
    Publication date: May 3, 2007
    Inventors: Wei Han, Zilun Hu, Timur Gungor
  • Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
    Patent number: 7205318
    Abstract: The present application describes lactam-containing cyclic diamines and derivatives thereof of Formula I: P4-M-M4I or pharmaceutically acceptable salt forms thereof, wherein M is a non-aromatic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Grant
    Filed: March 16, 2004
    Date of Patent: April 17, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jennifer X. Qiao, Tammy C. Wang, Gren Z. Wang, Timur Gungor
  • Thiazolidine compounds as calcium sensing receptor modulators
    Patent number: 7205322
    Abstract: The present invention relates to modulators of the calcium sensing receptor having the formula I wherein Ar1, X, J, R1, R2, R3, R7, R8 and Q are as defined herein.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: April 17, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Timur Gungor, John K. Dickson, Jr.
  • Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
    Patent number: 7169795
    Abstract: The present application describes sulfonylaminovalerolactams and derivatives thereof of Formula Ia–If: or pharmaceutically acceptable salt forms thereof, wherein ring G is a mono- or bicyclic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Grant
    Filed: September 28, 2004
    Date of Patent: January 30, 2007
    Assignee: Bristol Myers Squibb Company
    Inventors: Wei Han, Zilun Hu, Timur Gungor
  • N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
    Publication number: 20060293281
    Abstract: The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, D and W are as defined herein. These compounds are selective inhibitors of the human P2Y1 receptor which can be used as medicaments.
    Type: Application
    Filed: June 26, 2006
    Publication date: December 28, 2006
    Applicant: Bristol-Myers Squibb Company
    Inventors: Jennifer Qiao, Tammy Wang, James Sutton, Timur Gungor
  • Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
    Patent number: 7122557
    Abstract: The present application describes sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds and derivatives thereof of Formula I: P4-P-M-M4I or pharmaceutically acceptable salt forms thereof, wherein M is a ring, P is an optional ring, and P4 and M4 are as defined below. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Grant
    Filed: March 16, 2004
    Date of Patent: October 17, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Donald J. Pinto, Jennifer X. Qiao, Timur Gungor, Patrick Y. S. Lam, Yun-Long Li